Baxter has informed ASPEN that in addition to accepting direct orders, they have also reintroduced amino acids and Clinimix into the channel. Trading partners will begin to restock and continue to increase inventory upon customer request.
B Braun has notified ASPEN that their key amino acid products have been changed from 100% allocation to current customers to 120% allocation. They are building inventory and hope to have these products off allocation in the next couple of months.
Fresenius Kabi has notified ASPEN that they have an ample supply of Kabiven and Perikabiven, a three-chamber parenteral nutrition product containing amino acids, dextrose and lipid, and continues to be readily available for market use. Stocked inventory levels have been increased to support current demand as well as additional facilities who may be seeing an impact from market shortages.